1. A solid pharmaceutical composition suitable for oral administration that contains 3- (1.H.-indol-3-yl) -4- [2- (4-methylpiperazin-1-yl) quinazolin-4-yl] pyrrole- 2,5-dione or its pharmaceutically acceptable salt and at least one sizing, where the composition contains a sizing in an amount of from 2.5 to 12 wt.%, And the composition is in tablet form, where the total weight of the composition is the total weight of the tablet core . ! 2. The composition according to claim 1, where the composition contains a sizing agent in an amount of from 3 to 10 wt.% In terms of the total weight of the tablet core. ! 3. The composition according to claim 1 or 2, where the composition contains a compound in an amount of from 5 to 90 wt.% In terms of the total weight of the tablet core. ! 4. The composition according to claim 1 or 2, additionally containing at least one binder. ! 5. The composition according to claim 4, where the composition contains a binder in an amount of from 4 to 40 wt.% In terms of the total weight of the tablet core. ! 6. The composition according to claim 1 or 2, additionally containing at least one filler. ! 7. The composition according to claim 1 or 2, containing at least one additional excipient selected from a disintegrant, a slip improver, and a surfactant. ! 8. The composition according to claim 1 or 2, containing 3- (1.N.-indol-3-yl) -4- [2- (4-methylpiperazin-1-yl) quinazolin-4-yl] pyrrol-2 acetate 5-dione. ! 9. A solid pharmaceutical composition suitable for oral administration that contains 3- (1.H.-indol-3-yl) -4- [2- (4-methylpiperazin-1-yl) quinazolin-4-yl] pyrrole acetate -2,5-dione and at least one sizing, where the composition contains a sizing in an amount of from 3 to 5 wt.%, And the composition is in tablet form, where the total weight of the composition is1. Твердая фармацевтическая композиция, пригодная для орального введения, которая содержит 3-(1.H.-индол-3-ил)-4-[2-(4-метилпиперазин-1-ил)хиназолин-4-ил]пиррол-2,5-дион или его фарма
